Report Explores Future of Opioid Abuse-Resistant Formulations - - BioPharm International

ADVERTISEMENT

Report Explores Future of Opioid Abuse-Resistant Formulations



A new report from GBI Research reviews the current opioid-product market, analyzes the development pipeline, and reviews industry merger, acquisition, and licensing deals to develop a picture of the market through 2018. The increase in opioid use has led to an increase in abuse and consequently to increasing concern from doctors and regulators. As a result, approved drugs are differentiated increasingly by abuse-resistant technologies.

Many companies are working to develop abuse-resistant formulations of extended-release (ER) opioid analgesics, notes GBI Research. Most recent marketing approvals for ER opioids in the US have included risk evaluation and mitigation strategies that require license holders to provide physician training and raise patient awareness of opioid abuse. In many cases, post-marketing studies are required to examine the efficacy of abuse-resistant formulations. Initial post-marketing data reports for Embeda, which was launched in the US in 2009, are positive.

The current opioids market has a broad and highly diversified product profile, reports GBI Research. The developmental pipeline is small, however, and the market is relatively stagnant. Competition among abuse-resistant products is expected to be the driving factor in this market.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
EMA Warns of Falsified Herceptin Vials
April 16, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
Author Guidelines

Click here